{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:35:03Z","timestamp":1790087703268,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022336","name":"Esperion Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jacl.2023.12.005","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T17:26:06Z","timestamp":1704993966000},"page":"e153-e165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-5154","authenticated-orcid":false,"given":"P. Barton","family":"Duell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2620-9323","authenticated-orcid":false,"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2419-1476","authenticated-orcid":false,"given":"G.B. John","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-0954","authenticated-orcid":false,"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7180-769X","authenticated-orcid":false,"given":"Christine","family":"Broestl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8876-099X","authenticated-orcid":false,"given":"Anne C.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jacl.2023.12.005_bib0001","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.jacl.2023.12.005_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and treatment of heterozygous familial hypercholesterolemia","volume":"8","author":"McGowan","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jacl.2023.12.005_bib0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12944-017-0488-4","article-title":"Genetic determinants of inherited susceptibility to hypercholesterolemia - a comprehensive literature review","volume":"16","author":"Paththinige","year":"2017","journal-title":"Lipids Health Dis"},{"issue":"22","key":"10.1016\/j.jacl.2023.12.005_bib0004","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2023.12.005_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.001","article-title":"Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration","volume":"22","author":"Vallejo-Vaz","year":"2016","journal-title":"Atheroscler Suppl"},{"issue":"20","key":"10.1016\/j.jacl.2023.12.005_bib0006","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.jacl.2023.12.005_bib0007","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies","volume":"63","author":"Sniderman","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"32","key":"10.1016\/j.jacl.2023.12.005_bib0008","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.jacl.2023.12.005_bib0009","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacl.2023.12.005_bib0010","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"24","key":"10.1016\/j.jacl.2023.12.005_bib0011","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2023.12.005_bib0012","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2019.08.007","article-title":"Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry","volume":"289","author":"Duell","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacl.2023.12.005_bib0013","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2023.12.005_bib0014","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurjpc\/zwaa097","article-title":"Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study","volume":"28","author":"Gaudet","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2023.12.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105499","article-title":"Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the International Lipid Expert Panel (ILEP)","volume":"166","author":"Banach","year":"2021","journal-title":"Pharmacol Res"},{"issue":"8","key":"10.1016\/j.jacl.2023.12.005_bib0016","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2023.12.005_bib0017","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the Da Vinci study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2023.12.005_bib0018","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacl.2023.12.005_bib0019","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.jacl.2023.12.005_bib0020","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacl.2023.12.005_bib0021","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jacl.2023.12.005_bib0022","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.5114\/aoms\/141941","article-title":"PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021","volume":"17","author":"Banach","year":"2021","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jacl.2023.12.005_bib0023","unstructured":"Esperion Therapeutics Inc. NEXLETOL (bempedoic acid) prescribing information. Available at: https:\/\/pi.esperion.com\/nexletol\/nexletol-pi.pdf. Accessed March 30, 2023."},{"key":"10.1016\/j.jacl.2023.12.005_bib0024","unstructured":"Daiichi Sankyo Europe GmbH. NILEMDO (bempedoic acid). summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nilemdo-epar-product-information_en.pdf. Accessed March 30, 2023."},{"issue":"9","key":"10.1016\/j.jacl.2023.12.005_bib0025","first-page":"11","article-title":"Unmet need for further LDL-C lowering in India despite statin therapy: lipid association of India recommendations for the use of bempedoic acid","volume":"70","author":"Mehta","year":"2022","journal-title":"J Assoc Physicians India"},{"issue":"1","key":"10.1016\/j.jacl.2023.12.005_bib0026","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12929-016-0256-1","article-title":"The genetics and screening of familial hypercholesterolaemia","volume":"23","author":"Henderson","year":"2016","journal-title":"J Biomed Sci"},{"issue":"5","key":"10.1016\/j.jacl.2023.12.005_bib0027","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","article-title":"Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials","volume":"14","author":"Bays","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"10312","key":"10.1016\/j.jacl.2023.12.005_bib0028","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","article-title":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"398","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jacl.2023.12.005_bib0029","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.jacc.2021.09.004","article-title":"Familial hypercholesterolemia: JACC focus seminar 4\/4","volume":"78","author":"Brandts","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2023.12.005_bib0030","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2023.12.005_bib0031","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2023.12.005_bib0032","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","article-title":"Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial","volume":"320","author":"Rubino","year":"2021","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.jacl.2023.12.005_bib0033","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jacl.2021.05.002","article-title":"Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: A randomized, controlled trial","volume":"15","author":"Rubino","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"14","key":"10.1016\/j.jacl.2023.12.005_bib0034","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10106","key":"10.1016\/j.jacl.2023.12.005_bib0035","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.jacl.2023.12.005_bib0036","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacl.2023.12.005_bib0037","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.jacl.2023.12.005_bib0038","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jacl.2023.12.005_bib0039","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease Algorithm - 2020 Executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"20","key":"10.1016\/j.jacl.2023.12.005_bib0040","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1161\/CIRCULATIONAHA.117.027966","volume":"136","author":"Vallejo-Vaz","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2023.12.005_bib0041","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2021.01.009","article-title":"Lipid-lowering therapies: better together","volume":"320","author":"Banach","year":"2021","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.jacl.2023.12.005_bib0042","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2023.12.005_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.pcad.2023.03.001","article-title":"Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)","author":"Banach","year":"2023","journal-title":"Prog Cardiovasc Dis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287423003550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287423003550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T05:24:44Z","timestamp":1728969884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287423003550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1933287423003550"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2023.12.005","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2023.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}